Safety of hormone replacement therapy in gynaecological cancer survivors
Authors:
- 20 April 2012
- journal article
- review article
- Published by Taylor & Francis in Journal of Obstetrics and Gynaecology
- Vol. 32 (4) , 321-325
Abstract
Therapy for endometrial, ovarian and cervical cancer in young women can cause sudden onset of intense menopausal symptoms, such as hot flushes, emotional disorders and sexual dysfunction. In order to overcome these unpleasant and sometimes severe symptoms, hormone replacement therapy (HRT) has proven to be very effective. However, its safety remains controversial. We reviewed English literature and examined whether administration of HRT in this specific population is related with more recurrences and worse prognosis. Current scientific data, comprising mainly retrospective studies, suggest that recurrence rates and survival are comparable between HRT users and non-users. However, large randomised trials are missing and definitive conclusions cannot be drawn. Gynaecological cancer survivors using HRT, although they seem to have little if any risk for recurrence, should be correctly informed about the lack of strong evidence.Keywords
This publication has 34 references indexed in Scilit:
- Ovarian cancer and hormone replacement therapy in the Million Women StudyThe Lancet, 2007
- Does immediate hormone replacement therapy affect the oncologic outcome in endometrial cancer survivors?International Journal of Gynecological Cancer, 2006
- Randomized Double-Blind Trial of Estrogen Replacement Therapy Versus Placebo in Stage I or II Endometrial Cancer: A Gynecologic Oncology Group StudyJournal of Clinical Oncology, 2006
- Influence of Estrogen Plus Progestin on Breast Cancer and Mammography in Healthy Postmenopausal WomenJAMA, 2003
- Average Risks of Breast and Ovarian Cancer Associated with BRCA1 or BRCA2 Mutations Detected in Case Series Unselected for Family History: A Combined Analysis of 22 StudiesThe American Journal of Human Genetics, 2003
- ADENOCARCINOMA of the UTERUS2002
- A meta-analysis of estrogen replacement therapy and risk of epithelial ovarian cancerJournal of Clinical Epidemiology, 2000
- Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestagen therapy in postmenopausal womenThe Lancet, 1997
- Estrogen replacement in surgical stage I and II endometrial cancer survivorsAmerican Journal of Obstetrics and Gynecology, 1996
- Hormone replacement therapy and survival after surgery for ovarian cancer.BMJ, 1991